Retatrutide is supplied by RS Bio Labs strictly as a laboratory research material for qualified scientific personnel. It is not approved, intended or authorised for human consumption, self-administration, diagnostic, therapeutic or veterinary use. All findings referenced here are from published preclinical or clinical-trial literature and do not constitute medical advice or establish safety in any unapproved setting.
Retatrutide in one sentence
Retatrutide is a synthetic, fatty-acid-conjugated long-acting peptide that binds and activates three related metabolic receptors at once — the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Because it engages all three pathways, it is described in the literature as a "triple agonist" or "GGG tri-agonist", and it sits one generation beyond dual agonists such as Tirzepatide (GIP/GLP-1).
How does Retatrutide work?
The defining feature of Retatrutide is that a single molecule acts on three receptors that each sit at a different node of the body's energy-balance network. The combined effect is qualitatively different from any single- or dual-agonist compound:
- GLP-1 receptor: reproduces the appetite-suppression, slowed gastric emptying and glucose-dependent insulin secretion that decades of incretin research have characterised.
- GIP receptor: adds complementary insulinotropic activity and is studied for direct effects on adipose-tissue metabolism.
- Glucagon receptor: the differentiator — glucagon-receptor activation is associated in research models with increased resting energy expenditure and hepatic lipid mobilisation.
In short, Retatrutide is studied as a compound that reduces energy intake (via GLP-1/GIP) while simultaneously increasing energy expenditure (via glucagon) — a combination not achievable with monotherapy. For a deeper breakdown of how these three receptor systems differ, see GLP-1 vs GIP vs Glucagon agonists.
Why is Retatrutide significant?
The Phase 2 TRIUMPH-1 trial (Jastreboff et al., New England Journal of Medicine, 2023) studied Retatrutide in adults with obesity over 48 weeks. At the 12 mg dose, mean body-weight reduction reached approximately 24.2% — the largest effect reported for any incretin-class compound to date, and notably the dose-response curve had not plateaued by week 48. A parallel Phase 2 programme in metabolic dysfunction-associated steatohepatitis (MASH) reported substantial reductions in liver-fat content. Phase 3 development (including cardiovascular outcomes) is ongoing.
Semaglutide (GLP-1) delivered ~15% and Tirzepatide (GIP/GLP-1) ~22.5% in their respective pivotal trials. Retatrutide's ~24% at 48 weeks — still climbing — is what places the triple-agonist mechanism at the frontier of incretin research.
| Compound | Receptor targets | Peak trial weight change |
|---|---|---|
| Retatrutide | GIP + GLP-1 + Glucagon | ~24.2% (Ph2, 48 wk) |
| Tirzepatide | GIP + GLP-1 | ~22.5% (Ph3, 72 wk) |
| Semaglutide | GLP-1 | ~15% (Ph3, 68 wk) |
Forms, handling & half-life
Research-grade Retatrutide is supplied as a sterile lyophilised (freeze-dried) powder in sealed vials, measured in milligrams. Before use in a research setting it is reconstituted with bacteriostatic water; the vial is then kept refrigerated. Three companion guides cover the practical handling in detail:
- Reconstituting Retatrutide — mixing ratios, worked concentration examples and technique.
- Retatrutide storage guide — lyophilised vs reconstituted stability, temperatures and shelf life.
- Retatrutide half-life — why the ~6-day half-life supports a once-weekly research schedule.
Research status & safety context
As of 2026, Retatrutide remains an investigational compound. It has not been approved by the MHRA, FDA or any other regulator for any use, and it is not available as a medicine. Everything documented above is drawn from published clinical-trial and preclinical literature and is provided as a scientific reference only. Products sold by RS Bio Labs are research reagents for in vitro laboratory work and are not for human use.